Apogee's Eczema Drug Shows Promising Results, Challenging Industry Leaders
Apogee Therapeutics' promising eczema drug showed strong efficacy in Phase 2 trials, outperforming rivals like Sanofi's Dupixent, but its shares fell sharply after the announcement. The drug could potentially rival Sanofi's top revenue-generating treatments if further trials succeed, with plans for Phase 3 testing in 2026.